Roquefort Therapeutics plc (LON:ROQ – Get Free Report) traded down 4.8% during trading on Friday . The company traded as low as GBX 3.50 ($0.05) and last traded at GBX 3.60 ($0.05). 32,668 shares traded hands during trading, a decline of 89% from the average session volume of 299,896 shares. The stock had previously closed at GBX 3.78 ($0.05).
Roquefort Therapeutics Trading Down 4.8 %
The firm has a market cap of £4.65 million, a PE ratio of -360.00 and a beta of 0.05. The business’s 50-day simple moving average is GBX 4.09 and its 200 day simple moving average is GBX 4.96.
Roquefort Therapeutics Company Profile
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
See Also
- Five stocks we like better than Roquefort Therapeutics
- 5 discounted opportunities for dividend growth investors
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Why Are Stock Sectors Important to Successful Investing?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Bank Stocks – Best Bank Stocks to Invest In
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
